Published Jun 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

Member News
Copy The Link to the  Article
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.
Copy The Link to the  Article

Related or similar articles

View more News
December 10, 2021

Labshares Newton Doubles Space for Emerging Biotech Startups

NEWTON, Mass.--(BUSINESS WIRE)--Labshares Newton celebrated today the opening of 19,000 square feet of new incubator lab space and expects to open another 6,000-foot lab in September. Labshares’ new space incorporates 12 private suites, 15 lab ...
Labshares News
June 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.
Member News
March 26, 2019

Abcuro announces pre-clinical data on new immuno-oncology target

First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News